Contact: +1 650-308-4807 or Info@i-Runway.com

Follow us on:      

iRunway Research Cancer Immunotherapy iRunway Research Cancer Immunotherapy
   Sale of Checkpoint Inhibitor drugs
   estimated to grow at a CAGR of 32%.
This report examines the US patent landscape of antibody therapy for treating Cancer.
What's Inside?
  Analysis of Cancer Immunotherapy IP Landscape    
Free Research Report

The report examines patenting activities across various aspects of cancer immunotherapy, including the most researched types of cancer.

 
   
 Comparison of Patent Portfolios  

Genentech filed 1000+ patents in 2002, but abandoned over 900 applications; University of California owns the largest IP portfolio in cancer antibody therapy in the US.

 
   
 Analysis of Clinical Trials  

88% increase in clinical trials between 2014-2015 shows growing acceptance of antibody therapy for cancer.

Applications-based Distribution of Patents in Cancer Immunotherapy

 

 

 
iRunway Research Cancer Immunotherapy Patent Distribution
 
   
   

    Austin   •   Santa Clara   •   Denver   •   Bangalore

© Copyright iRunway 2016